Minerva Neurosciences, Inc. (NERV) News
Follow Minerva Neurosciences, Inc. (NERV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Minerva Neurosciences Posts Q3 Profit on Non-Cash Warrant Gain
EQUITY | Nov 06, 2026, 02:26 PM UTC
M
Minerva Neurosciences Reports Q3 2026 Net Income of $100.7 Million
Third-quarter GAAP net income included a $109.6 million non-cash gain from changes in warrant-liability fair value. Excluding that gain and stock-based compensation, the company posted an adjusted net loss of $5.6 millio
EQUITY | Nov 06, 2026, 02:13 PM UTC
L
NERV: Roluperidone's pivotal phase III trial is on track, with results expected next year and strong investor support
The conference highlighted progress in developing roluperidone for negative symptoms of schizophrenia, with a confirmatory phase III trial underway and results expected in the second half of next year. Strong IP protecti
EQUITY | Sep 09, 2026, 08:15 PM UTC
L
NERV says roluperidone phase III trial is on track; results due next year
NERV is advancing roluperidone for negative symptoms of schizophrenia with a confirmatory phase III trial underway. Results are expected in the second half of next year.
EARNINGS | Sep 09, 2026, 07:43 PM UTC
L
Minerva Neurosciences to participate in two upcoming investor conferences
Minerva Neurosciences plans to participate in two upcoming investor conferences.
EQUITY | Aug 28, 2026, 12:07 PM UTC
L
NERV - Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
NERV - Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
EQUITY | Aug 28, 2026, 12:00 PM UTC
L
Analysts raise views on CAPR, DLR, FOXA, LTC, NERV, NYAX
Analysts upgrade CAPR to Overweight at Cantor, DLR to Buy at HSBC, FOXA to Overweight at JPM, LTC to Outperform at RBC, NERV to Buy at Jefferies, and NYAX to Outperform at Keefe.
EQUITY | Aug 14, 2026, 10:28 AM UTC